Clinical Characteristics and Outcomes of COVID-19 in 1294 New Cancer Patients: Single-Center, Prospective Cohort Study from Iran

Fazilat‐Panah, Danial; Tafti, Hamid Fallah; Rajabzadeh, Yavar; Fatemi, Maedeh Alsadat; Ahmadi, Nahid; Jahansouz, Davoud; Tabasi, Mohsen; Javadinia, Seyed Alireza; Joudi, Marjan; Harati, Hadi; Attarian, Fahimeh; Taghizadeh‐Hesary, Farzad

doi:10.1080/07357907.2022.2075376

Cited by 11 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with hematologic malignancies are susceptible to COVID-19 due to dysfunction of the humoral and cellular immune systems, cytotoxic chemotherapy, and old age ( 14 , 15 ). Studies showed that immune response (seroconversion) rates following COVID-19 vaccination in patients with underlying diseases such as cancer patients are compromised in older patients, those with hematological malignancies, and chemotherapy receivers ( 16 , 17 ).…”

Section: Sars-cov-2 and Patients With Cancermentioning

confidence: 99%

COVID-19 vaccination in patients with cancer: Opportunities and challenges

Al‐qaim¹,

Owadh²,

Ali³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

The rapid spread of the SARS-Cov-2 virus, the increase in the number of patients with severe COVID-19, and the high mortality rate created the basis for the production of safe and effective vaccines. Studies have confirmed the increased risk of severe Covid-19 disease and mortality in cancer patients. It is logical that cancer patients should be the first to receive the primary vaccination and the booster vaccine for Covid-19. Since studies related to cancer patients and the effectiveness of existing Covid-19 vaccines have not been widely conducted, there are significant uncertainties about the effectiveness of the vaccine and the level of humoral and cellular immune responses in these patients. As a result, the possible risks and side effects of existing vaccines are not clear for patients with different cancers who are undergoing special treatments. In this study, we will discuss the effectiveness and safety of existing vaccines on cancer patients. In addition, we highlight factors that could affect the effectiveness of vaccines in these patients and finally discuss opportunities and challenges related to vaccination in cancer patients.

show abstract

Section: Sars-cov-2 and Patients With Cancermentioning

confidence: 99%

COVID-19 vaccination in patients with cancer: Opportunities and challenges

Al‐qaim¹,

Owadh²,

Ali³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Based on evidence, COVID-19 causes a significant higher rate of mortality in cancer patients ( 17 – 19 ). Regarding the fact that cancer is also more prevalent in the elderlies, a predictor of poor serologic response to COVID-19 vaccine ( 11 ), it is very important to assess the efficacy, durability, and safety of BBIBP-CorV vaccine (the most common vaccine used in Iran) among cancer patients to prevent a possible outbreak of COVID-19 infection in vaccinated but actually unprotected individuals.…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study

Tameshkel

Dargoush²,

Amirkalali³

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundLong-term safety and efficacy of BBIBP-CorV vaccine especially in individuals with chronic diseases, like cancer, is under investigation. In the present prospective study, we aimed to evaluate severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody response with BBIBP-CorV vaccine in Iranian cancer patients.MethodsAll the patients registered to receive BBIBP-CorV (Sinopharm) vaccine were divided into two groups of with (cases = 107) and without (controls = 45) history of cancer. Serum levels of SARS-CoV anti-spike recombinant receptor binding domain (anti-sRBD) and anti-nucleocapsid (anti-N) IgG serum levels were measured on days 0 (phase 0), 28–32 (phase I), and 56–64 (phase II) of vaccination. The data were analyzed using SPSS, version 22.ResultsTotally, 152 individuals (67.1% females) with the mean age of 46.71 ± 15.36 years were included. Solid cancers included 87.8% of the cancer cases (46.7% gynecological and 31.8% gastrointestinal cancer). At Phases I and II, positive anti-sRBD IgG and anti-N IgG were significantly lower among the cases in total analysis. Side effects were not significantly different between the cases and controls. The lowest positive anti-sRBD IgG test was observed among the cancer patients who were simultaneously receiving chemotherapy (35.3%). Anti-sRBD IgG and anti-N IgG serum levels significantly increased at phases I and II in total analysis and in each group. In addition, serum anti-sRBD IgG increased during the three phases and it was significantly higher in the control group.ConclusionFull vaccination of COVID-19 by BBIBP-CorV in immunocompromised patients such as cancer patients is safe and effective and could induce antibody response but in lower levels compared to healthy people. Probable causes to have minor antibody response found in males, older ages, individuals with BMI ≥ 25, those without past history of COVID-19 and with hematologic cancers. No significant side effects after vaccination were seen.

show abstract

“…During this period, palliative care patients had longer hospital stays, higher mortality and infection rates, and poorer prognosis. Demand for palliative care is rising among cancer patients, putting them at risk of contracting COVID‐19 (Almeida et al, 2022; de Oliveira, da Costa Rosa, et al, 2021; de Oliveira, Rosa, et al, 2021; Fazilat‐Panah et al, 2022; Jeba, 2020; Moriyama et al, 2021; Onesti et al, 2021; Rahnea‐Nita et al, 2021; Strang et al, 2021; Tashkandi et al, 2021). Palliative care facilities have also been hit by the viral outbreak.…”

Section: Introductionmentioning

confidence: 99%

Palliative care for cancer patients during the COVID‐19 pandemic: A narrative synthesis from 36 studies of 16 countries

Zhao

et al. 2023

Journal of Clinical Nursing

View full text Add to dashboard Cite

BackgroundDuring the COVID‐19 epidemic, palliative care has become even more indispensable for cancer patients.AimTo identify the changes in palliative care for cancer patients and improvements in palliative care quality during the COVID‐19 pandemic.DesignA systematic review and narrative synthesis was conducted in PubMed, Embase and Web of Science. An evaluation tool using mixed methods was used to assess the quality of the study. The main relevant themes identified were used to group qualitative and quantitative findings.ResultsA total of 36 studies were identified, primarily from different countries, with a total of 14,427 patients, 238 caregivers and 354 health care providers. Cancer palliative care has been experiencing several difficulties following the COVID‐19 pandemic, including increased mortality and infection rates as well as delays in patient treatment that have resulted in poorer prognoses. Treatment providers are seeking solutions such as electronic management of patients and integration of resources to care for the mental health of patients and staff. Telemedicine plays an important role in many ways but cannot completely replace traditional treatment. Clinicians strive to meet patients' palliative care needs during special times and improve their quality of life.ConclusionsPalliative care faces unique challenges during the COVID‐19 epidemic. With adequate support to alleviate care‐related challenges, patients in the home versus hospital setting will be able to receive better palliative care. In addition, this review highlights the importance of multiparty collaboration to achieve personal and societal benefits of palliative care.Patient or Public ContributionNo Patient or Public Contribution.

show abstract

Clinical Characteristics and Outcomes of COVID-19 in 1294 New Cancer Patients: Single-Center, Prospective Cohort Study from Iran

Cited by 11 publications

References 41 publications

COVID-19 vaccination in patients with cancer: Opportunities and challenges

COVID-19 vaccination in patients with cancer: Opportunities and challenges

SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study

Palliative care for cancer patients during the COVID‐19 pandemic: A narrative synthesis from 36 studies of 16 countries

Contact Info

Product

Resources

About